Charles River Laboratories Intl. Inc vs Intuit Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Intuit Inc. trades at $302.36 (market cap $81.21B). The key difference: Intuit Inc. is far larger — about 5.7× Charles River Laboratories Intl. Inc's market cap, and Intuit Inc. pays a 1.82% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Intuit Inc. for 66 Days on average.
| CRL | INTU | |
|---|---|---|
Market Cap | $14.23B | $81.21B |
Volume | 1,176,885 | 5,165,806 |
Sector | Health | Technology |
52-Week High | $310.77 | $683.39 |
52-Week Low | $149.93 | $255.07 |
Typical Hold Time | 33 Days | 66 Days |
Enterprise Value | $17.06B | $82.43B |
Dividend Yield | — | 1.82% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Intuit (INTU) trades at $297.24, up 2.56% today, with strong fundamentals including 21.29% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed moving averages, with key support at $293 and resistance at $300. Recent news highlights growth in QuickBooks monetization and AI initiatives, though overshadowed by multiple class action lawsuits filed in early September 2026.
Outlook remains positive with analyst consensus target of $379.68 (27.7% upside), supported by robust revenue growth and expanding margins. Key risks include legal overhang from securities litigation and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, but investors should monitor lawsuit developments and Q3 2026 earnings due soon.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →